Chromocell Unveils Its Injectable Depot Program Utilizing Peripheral Nerve Blocks For The Treatment Of Post-Operative Pain
Chromocell Unveils Its Injectable Depot Program Utilizing Peripheral Nerve Blocks For The Treatment Of Post-Operative Pain
Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain.
開發非阿片類疼痛治療療法的先驅Chromocell Therapeutics Corporation（「Chromocell」，或 「公司」）（紐約證券交易所代碼：CHRO）今天宣佈推出其利用周圍神經阻滯治療術後疼痛的可注射倉庫計劃。該倉庫計劃基於該公司用於治療慢性疼痛和眼痛的新型Nav1.7分子。
There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product.
在美國，每年大約進行70萬例膝關節置換術和500,000例肩關節置換術，這種鎮痛方式可能適用於這些手術，這爲該產品提供了強大的潛在市場。
